About romidepsin
Histone deacetylase inhibitor
Used for
- Treatment of cutaneous T-cell lymphoma after at least one prior systemic therapy
- Treatment of peripheral T-cell lymphoma after at least one prior therapy
Usual adult dose
14 mg/m² by intravenous infusion over 4 hours on days 1, 8, and 15 of each 28-day cycle, if tolerated.
Common side effects
- Nausea, vomiting, diarrhea, and loss of appetite
- Low blood cell counts and increased infection risk
- Fatigue and weakness
- Electrocardiogram changes, including QT prolongation
Important warnings
- Can cause serious infections and dangerously low blood counts.
- May prolong the QT interval; correct low potassium or magnesium and monitor heart rhythm when appropriate.
- Severe skin reactions and tumor lysis syndrome have been reported.
- Avoid during pregnancy; effective contraception is recommended during treatment.
Pregnancy
May harm an unborn baby. Human pregnancy data are limited; avoid use during pregnancy.
Breastfeeding
Breastfeeding is not recommended during treatment and for one week after the final dose.
Interactions
- Strong CYP3A4 inhibitors can increase romidepsin exposure.
- Strong CYP3A4 inducers can reduce romidepsin exposure.
- Medicines that prolong the QT interval may increase heart-rhythm risks.
- Warfarin may require closer monitoring of blood clotting.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.